

































## REFERENCES

- [1] M.E. Domino, M.S. Swartz, Who are the new users of antipsychotic medications?, *Psychiatr Serv* 59(5) (2008) 507-14.
- [2] M. Arranz, J. Perez-Blanco, B. Arias, Pharmacogenetics of the efficacy of antipsychotic drugs in Schizophrenia, in: J. Rybakowski, A. Serretti (Eds.), *Genetic influences on response to drug treatment for major psychiatric disorders*, Adis2016.
- [3] T. Cabaleiro, R. López-Rodríguez, M. Román, D. Ochoa, J. Novalbos, A. Borobia, A. Carcas, F. Abad-Santos, Pharmacogenetics of quetiapine in healthy volunteers: association with pharmacokinetics, pharmacodynamics, and adverse effects, *Int Clin Psychopharmacol* 30(2) (2015) 82-8.
- [4] F. Czerwensky, S. Leucht, W. Steimer, CYP1A2\*1D and \*1F polymorphisms have a significant impact on olanzapine serum concentrations, *Ther Drug Monit* 37(2) (2015) 152-60.
- [5] S.A. Ivanova, M.L. Filipenko, N.M. Vyalova, E.N. Voronina, I.V. Pozhidaev, D.Z. Osmanova, M.V. Ivanov, O.Y. Fedorenko, A.V. Semke, N.A. Bokhan, CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects, *Bull Exp Biol Med* 160(5) (2016) 687-90.
- [6] S.A. Ivanova, V.A. Toshchakova, M.L. Filipenko, O.Y. Fedorenko, E.G. Boyarko, A.S. Boiko, A.V. Semke, N.A. Bokhan, L.I. Aftanas, A.J. Loonen, Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility, *World J Biol Psychiatry* 16(3) (2015) 200-5.
- [7] M.M. Jukic, R.L. Smith, T. Haslemo, E. Molden, M. Ingelman-Sundberg, Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study, *Lancet Psychiatry* 6(5) (2019) 418-426.
- [8] K.A. Oshikoya, K.M. Neely, R.J. Carroll, I.T. Aka, A.C. Maxwell-Horn, D.M. Roden, S.L. Van Driest, CYP2D6 genotype and adverse events to risperidone in children and adolescents, *Pediatr Res* 85(5) (2019) 602-606.
- [9] F. OY, L. AJM, V. NM, B. AS, P. IV, O. DZ, Hyperprolactinemia and CYP2D6, DRD2 and HTR2C genes polymorphisms in patients with schizophrenia, *Physiology and Pharmacology* 21(1) (2017) 25-33.
- [10] A.A. Kurylev, V.M. Brodyansky, B.V. Andreev, A.O. Kibitov, O.V. Limankin, S.N. Mosolov, The combined effect of CYP2D6 and DRD2 Taq1A polymorphisms on the antipsychotics daily doses and hospital stay duration in schizophrenia inpatients (observational naturalistic study), *Psychiatr Danub* 30(2) (2018) 157-163.
- [11] S. Thümmeler, E. Dor, R. David, G. Leali, M. Battista, A. David, F. Askenazy, C. Verstuyft, Pharmacoresistant Severe Mental Health Disorders in Children and Adolescents: Functional Abnormalities of Cytochrome P450 2D6, *Front Psychiatry* 9 (2018) 2.
- [12] I. Piatkov, D. Caetano, Y. Assur, S.L. Lau, M. Coelho, T. Jones, T. Nguyen, S. Boyages, M. McLean, CYP2C19\*17 protects against metabolic complications of clozapine treatment, *World J Biol Psychiatry* 18(7) (2017) 521-527.
- [13] K. Vasudev, Y.H. Choi, R. Norman, R.B. Kim, U.I. Schwarz, Genetic Determinants of Clozapine-Induced Metabolic Side Effects, *Can J Psychiatry* 62(2) (2017) 138-149.
- [14] S. Hattori, A. Suda, M. Miyauchi, Y. Shiraishi, T. Saeki, T. Fukushima, M. Fujibayashi, N. Tsujita, C. Ishii, N. Ishii, T. Moritani, Y. Saigusa, I. Kishida, The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine, *BMC Psychiatry* 20(1) (2020) 72.
- [15] I. Piatkov, D. Caetano, Y. Assur, S.L. Lau, T. Jones, S.C. Boyages, M. McLean, ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine, *Pharmgenomics Pers Med* 10 (2017) 235-242.
- [16] F. Corponi, C. Fabbri, G. Boriani, I. Diemberger, D. Albani, G. Forloni, A. Serretti, Corrected QT Interval Prolongation in Psychopharmacological Treatment and Its Modulation by Genetic Variation, *Neuropsychobiology* 77(2) (2019) 67-72.



- [17] A.E. Anil Yağcıoğlu, G. Yoca, Y. Ayhan, R. Karaca, L. Çevik, A. Müderrisoğlu, M.T. Gökteş, N. Eni, M.K. Yazıcı, A. Bozkurt, M.O. Babaoğlu, C.-A.L.S. Group, Relation of the Allelic Variants of Multidrug Resistance Gene to Agranulocytosis Associated With Clozapine, *J Clin Psychopharmacol* 36(3) (2016) 257-61.
- [18] E. Sangüesa, C. Cirujeda, J. Concha, P.P. Padilla, M.P. Ribate, C.B. García, Implementation of pharmacogenetics in a clozapine treatment resistant patient: a case report, *Pharmacogenomics* 20(12) (2019) 871-877.
- [19] P. Mian, M. Somers, M.T. Berg, W. Cahn, I. Wilting, R.V. Schaik, High levels of several antipsychotics and antidepressants due to a pharmacogenetic cause: a case report, *Pharmacogenomics* 20(8) (2019) 567-570.
- [20] D. Amato, A.C. Vernon, F. Papaleo, Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability, *Neurosci Biobehav Rev* 85 (2018) 146-159.
- [21] R. Escamilla, B. Camarena, R. Saracco-Alvarez, A. Fresán, S. Hernández, A. Aguilar-García, Association study between, *Neuropsychiatr Dis Treat* 14 (2018) 2981-2987.
- [22] J. Han, Y. Li, X. Wang, Potential link between genetic polymorphisms of, *Neuropsychiatr Dis Treat* 13 (2017) 2935-2943.
- [23] E. Huang, M. Maciukiewicz, C.C. Zai, A.K. Tiwari, J. Li, S.G. Potkin, J.A. Lieberman, H.Y. Meltzer, D.J. Müller, J.L. Kennedy, Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response, *Pharmacogenomics* 17(2) (2016) 103-9.
- [24] J.P. Zhang, D.G. Robinson, J.A. Gallego, M. John, J. Yu, J. Addington, M. Tohen, J.M. Kane, A.K. Malhotra, T. Lencz, Association of a Schizophrenia Risk Variant at the DRD2 Locus With Antipsychotic Treatment Response in First-Episode Psychosis, *Schizophr Bull* 41(6) (2015) 1248-55.
- [25] W. Zhou, Y. Xu, Q. Lv, Y.H. Sheng, L. Chen, M. Li, L. Shen, C. Huai, Z. Yi, D. Cui, S. Qin, Genetic Association of Olanzapine Treatment Response in Han Chinese Schizophrenia Patients, *Front Pharmacol* 10 (2019) 177.
- [26] E. Maffioletti, P. Valsecchi, A. Minelli, C. Magri, C. Bonvicini, S. Barlati, E. Sacchetti, A. Vita, M. Gennarelli, Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients, *Drug Dev Res* 81(6) (2020) 754-761.
- [27] J. Li, H. Hashimoto, H.Y. Meltzer, Association of Serotonin, *Front Psychiatry* 10 (2019) 58.
- [28] W. Zhou, W. Chang, Y. Yan, L. Shen, W. Li, Z. Yi, S. Qin, Pharmacogenetics analysis of serotonin receptor gene variants and clinical response to risperidone in Han Chinese schizophrenic patients, *Neurosci Lett* 683 (2018) 202-206.
- [29] A. Jajodia, H. Kaur, K. Kumari, N. Kanojia, M. Gupta, R. Baghel, M. Sood, S. Jain, R.K. Chadda, R. Kukreti, Evaluation of genetic association of neurodevelopment and neuroimmunological genes with antipsychotic treatment response in schizophrenia in Indian populations, *Mol Genet Genomic Med* 4(1) (2016) 18-27.
- [30] J.R. Bishop, J.L. Reilly, M.S. Harris, S.R. Patel, R. Kittles, J.A. Badner, K.M. Prasad, V.L. Nimgaonkar, M.S. Keshavan, J.A. Sweeney, Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia, *Psychopharmacology (Berl)* 232(1) (2015) 145-54.
- [31] W. Liang, H. Yu, Y. Su, T. Lu, H. Yan, W. Yue, D. Zhang, Variants of GRM7 as risk factor and response to antipsychotic therapy in schizophrenia, *Transl Psychiatry* 10(1) (2020) 83.
- [32] H. Kaneko, I. Miura, K. Kanno-Nozaki, S. Horikoshi, M. Hino, H. Yabe, Val 108/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia, *Neuropsychiatr Dis Treat* 14 (2018) 1657-1663.
- [33] Q. Xu, M. Li, S. Qin, Y. Li, A. Ning, Y. Fu, D. Wang, D. Zeng, H. Li, W. Yu, S. Yu, Two Novel Loci of, *Front Pharmacol* 11 (2020) 7.
- [34] A.E. Shindler, E.L. Hill-Yardin, S. Petrovski, N. Bishop, A.E. Franks, Towards Identifying Genetic Biomarkers for Gastrointestinal Dysfunction in Autism, *J Autism Dev Disord* 50(1) (2020) 76-86.
- [35] M. Mitjans, R. Catalán, M. Vázquez, A. González-Rodríguez, R. Penadés, A. Pons, G. Massana, J. Munro, M.J. Arranz, B. Arias, Hypothalamic-pituitary-adrenal system, neurotrophic factors and

- clozapine response: association with FKBP5 and NTRK2 genes, *Pharmacogenet Genomics* 25(5) (2015) 274-7.
- [36] F. Guan, T. Zhang, W. Han, L. Zhu, T. Ni, H. Lin, D. Liu, G. Chen, J. Xiao, T. Li, Relationship of SNAP25 variants with schizophrenia and antipsychotic-induced weight change in large-scale schizophrenia patients, *Schizophr Res* 215 (2020) 250-255.
- [37] F.M. Daray, D. Rodante, L.G. Carosella, M.E. Silva, M. Martínez, M.V. Fernández Busch, D.F. Faccone, R.P. Rothlin, P.C. Maffía, -759C>T Polymorphism of the HTR2C Gene is Associated with Second Generation Antipsychotic-Induced Weight Gain in Female Patients with Schizophrenia, *Pharmacopsychiatry* 50(1) (2017) 14-18.
- [38] G.P. Reynolds, Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review, *Clin Psychopharmacol Neurosci* 10(2) (2012) 71-7.
- [39] J.P. Zhang, T. Lencz, R.X. Zhang, M. Nitta, L. Maayan, M. John, D.G. Robinson, W.W. Fleischhacker, R.S. Kahn, R.A. Ophoff, J.M. Kane, A.K. Malhotra, C.U. Correll, Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis, *Schizophr Bull* 42(6) (2016) 1418-1437.
- [40] C. Schröder, F. Czerwensky, S. Leucht, W. Steimer, Fat Mass and Obesity-Related Gene Variants rs9939609 and rs7185735 are Associated with Second-Generation Antipsychotic-Induced Weight Gain, *Pharmacopsychiatry* 52(1) (2019) 16-23.
- [41] S. Ryu, I.S. Huh, E.Y. Cho, Y. Cho, T. Park, S.C. Yoon, Y.H. Joo, K.S. Hong, Association Study of 60 Candidate Genes with Antipsychotic-induced Weight Gain in Schizophrenia Patients, *Pharmacopsychiatry* 49(2) (2016) 51-6.
- [42] M. Maciukiewicz, I. Gorbovskaia, A.K. Tiwari, C.C. Zai, N. Freeman, H.Y. Meltzer, J.L. Kennedy, D.J. Müller, Genetic validation study of protein tyrosine phosphatase receptor type D (PTPRD) gene variants and risk for antipsychotic-induced weight gain, *J Neural Transm (Vienna)* 126(1) (2019) 27-33.
- [43] K. Mittal, V.F. Gonçalves, R. Harripaul, A.B. Cuperfain, B. Rollins, A.K. Tiwari, C.C. Zai, M. Maciukiewicz, D.J. Müller, M.P. Vawter, J.L. Kennedy, A comprehensive analysis of mitochondrial genes variants and their association with antipsychotic-induced weight gain, *Schizophr Res* 187 (2017) 67-73.
- [44] A. Delacrétaz, A. Zdravovic, F. Vandenberghe, N. Saigi-Morgui, A. Glatard, L. Quteineh, M. Gholam-Rezaee, W. Raffoul, L.A. Applegate, P. Jafari, F. Gamma, A. von Gunten, P. Conus, C.B. Eap, Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs, *Gene* 628 (2017) 8-15.
- [45] B. Misiak, L. Laczanski, N.K. Sloka, E. Szmida, R. Slezak, P. Piotrowski, A. Kiejna, D. Frydecka, Genetic Variation in One-Carbon Metabolism and Changes in Metabolic Parameters in First-Episode Schizophrenia Patients, *Int J Neuropsychopharmacol* 20(3) (2017) 207-212.
- [46] I.V. Pozhidaev, D.Z. Paderina, O.Y. Fedorenko, E.G. Kornetova, A.V. Semke, A.J.M. Loonen, N.A. Bokhan, B. Wilffert, S.A. Ivanova, 5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia, *Front Mol Neurosci* 13 (2020) 63.
- [47] B. Lerer, R.H. Segman, E.C. Tan, V.S. Basile, R. Cavallaro, H.N. Aschauer, R. Strous, S.A. Chong, U. Heresco-Levy, M. Verga, J. Scharfetter, H.Y. Meltzer, J.L. Kennedy, F. Macciardi, Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype, *Int J Neuropsychopharmacol* 8(3) (2005) 411-25.
- [48] H.J. Lee, S.G. Kang, Genetics of tardive dyskinesia, *Int Rev Neurobiol* 98 (2011) 231-64.
- [49] M.J. Arranz, M. Rivera, J.C. Munro, Pharmacogenetics of response to antipsychotics in patients with schizophrenia, *CNS Drugs* 25(11) (2011) 933-69.
- [50] A.S. Boiko, S.A. Ivanova, I.V. Pozhidaev, M.B. Freidin, D.Z. Osmanova, O.Y. Fedorenko, A.V. Semke, N.A. Bokhan, B. Wilffert, A.J.M. Loonen, Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of, *World J Biol Psychiatry* 21(1) (2020) 72-77.

- [51] J.Y. Lu, A.K. Tiwari, G.C. Zai, A. Rastogi, S.A. Shaikh, D.J. Müller, A.N. Voineskos, S.G. Potkin, J.A. Lieberman, H.Y. Meltzer, G. Remington, A.H.C. Wong, J.L. Kennedy, C.C. Zai, Association study of Disrupted-In-Schizophrenia-1 gene variants and tardive dyskinesia, *Neurosci Lett* 686 (2018) 17-22.
- [52] M.S. Maes, J.Y. Lu, A.K. Tiwari, N. Freeman, V. de Luca, D.J. Müller, A.N. Voineskos, S.G. Potkin, J.A. Lieberman, H.Y. Meltzer, G. Remington, J.L. Kennedy, C.C. Zai, Schizophrenia-associated gene dysbindin-1 and tardive dyskinesia, *Drug Dev Res* (2020).
- [53] C.C. Zai, A.K. Tiwari, N.I. Chowdhury, Z. Yilmaz, V. de Luca, D.J. Müller, S.G. Potkin, J.A. Lieberman, H.Y. Meltzer, A.N. Voineskos, G. Remington, J.L. Kennedy, Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia, *World J Biol Psychiatry* 20(1) (2019) 91-95.
- [54] I. Spellmann, M.A. Reinhard, D. Veverka, P. Zill, M. Obermeier, S. Dehning, R. Schennach, N. Müller, H.J. Möller, M. Riedel, R. Musil, QTc prolongation in short-term treatment of schizophrenia patients: effects of different antipsychotics and genetic factors, *Eur Arch Psychiatry Clin Neurosci* 268(4) (2018) 383-390.
- [55] C. Sukasem, N. Vanwong, P. Srisawasdi, N. Ngamsamut, N. Nuntamool, Y. Hongkaew, A. Puangpetch, B. Chamkrachangpada, P. Limsila, Pharmacogenetics of Risperidone-Induced Insulin Resistance in Children and Adolescents with Autism Spectrum Disorder, *Basic Clin Pharmacol Toxicol* 123(1) (2018) 42-50.
- [56] D. Boloc, N. Rodríguez, T. Torres, S. García-Cerro, M. Parellada, J. Saiz-Ruiz, M.J. Cuesta, M. Bernardo, P. Gassó, A. Lafuente, S. Mas, J.A. Arnaiz, Identifying key transcription factors for pharmacogenetic studies of antipsychotics induced extrapyramidal symptoms, *Psychopharmacology (Berl)* 237(7) (2020) 2151-2159.
- [57] C.C. Zai, M.S. Maes, A.K. Tiwari, G.C. Zai, G. Remington, J.L. Kennedy, Genetics of tardive dyskinesia: Promising leads and ways forward, *J Neurol Sci* 389 (2018) 28-34.
- [58] M.J. Arranz, J. Munro, J. Birkett, A. Bolonna, D. Mancama, M. Sodhi, K.P. Lesch, J.F. Meyer, P. Sham, D.A. Collier, R.M. Murray, R.W. Kerwin, Pharmacogenetic prediction of clozapine response, *Lancet* 355(9215) (2000) 1615-6.
- [59] M. Gupta, N.S. Moily, H. Kaur, A. Jajodia, S. Jain, R. Kukreti, Identifying a predictive model for response to atypical antipsychotic monotherapy treatment in south Indian schizophrenia patients, *Genomics* 102(2) (2013) 131-5.
- [60] B.S. Lee, R.S. McIntyre, J.E. Gentle, N.S. Park, D.A. Chiriboga, Y. Lee, S. Singh, M.A. McPherson, A computational algorithm for personalized medicine in schizophrenia, *Schizophr Res* 192 (2018) 131-136.
- [61] T.R. Tonozzi, G.D. Braunstein, A. Kammesheidt, C. Curran, S. Golshan, J. Kelsoe, Pharmacogenetic profile and major depressive and/or bipolar disorder treatment: a retrospective, cross-sectional study, *Pharmacogenomics* 19(15) (2018) 1169-1179.
- [62] S. Mas, P. Gassó, M.A. Ritter, C. Malagelada, M. Bernardo, A. Lafuente, Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: multilocus interaction in the mTOR pathway, *Eur Neuropsychopharmacol* 25(1) (2015) 51-9.
- [63] M.J. Arranz, J. Munro, S. Osborne, D. Collier, R.W. Kerwin, Difficulties in replication of results, *Lancet* 356(9238) (2000) 1359-60.
- [64] H.T. Corfitsen, B. Krantz, A. Larsen, A. Drago, Molecular pathway analysis associates alterations in obesity-related genes and antipsychotic-induced weight gain, *Acta Neuropsychiatr* 32(2) (2020) 72-83.
- [65] S.E. Ter Hark, S. Jamain, D. Schijven, B.D. Lin, M.K. Bakker, A. Boland-Auge, J.F. Deleuze, R. Troudet, A.K. Malhotra, S. Gülöksüz, C.H. Vinkers, B.H. Ebdrup, R.S. Kahn, M. Leboyer, J.J. Luykx, A new genetic locus for antipsychotic-induced weight gain: A genome-wide study of first-episode psychosis patients using amisulpride (from the OPTiMiSE cohort), *J Psychopharmacol* 34(5) (2020) 524-531.
- [66] H. Yu, L. Wang, L. Lv, C. Ma, B. Du, T. Lu, C. Jin, H. Yan, Y. Yang, W. Li, Y. Ruan, H. Zhang, W. Mi, B. Mowry, W. Ma, K. Li, D. Zhang, W. Yue, Genome-Wide Association Study Suggested the PTPRD Polymorphisms Were Associated With Weight Gain Effects of Atypical Antipsychotic Medications, *Schizophr Bull* 42(3) (2016) 814-23.

- [67] H. Yu, H. Yan, L. Wang, J. Li, L. Tan, W. Deng, Q. Chen, G. Yang, F. Zhang, T. Lu, J. Yang, K. Li, L. Lv, Q. Tan, H. Zhang, X. Xiao, M. Li, X. Ma, F. Yang, L. Li, C. Wang, T. Li, D. Zhang, W. Yue, C.A.P. Consortium, Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study, *Lancet Psychiatry* 5(4) (2018) 327-338.
- [68] D. Wang, D.J. Fu, X. Wu, A. Shapiro, R. Favis, A. Savitz, H. Chung, L. Alphas, S. Gopal, M. Haas, N. Cohen, Q. Li, Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia, *Pharmacogenet Genomics* 25(4) (2015) 173-85.
- [69] E.S. Ovenden, B.I. Drögemöller, L. van der Merwe, B. Chiliza, L. Asmal, R.A. Emsley, L. Warnich, Fine-mapping of antipsychotic response genome-wide association studies reveals novel regulatory mechanisms, *Pharmacogenomics* 18(2) (2017) 105-120.
- [70] E.J. Brandl, A.K. Tiwari, C.C. Zai, E.L. Nurmi, N.I. Chowdhury, T. Arenovich, M. Sanches, V.F. Goncalves, J.J. Shen, J.A. Lieberman, H.Y. Meltzer, J.L. Kennedy, D.J. Müller, Genome-wide association study on antipsychotic-induced weight gain in the CATIE sample, *Pharmacogenomics J* 16(4) (2016) 352-6.
- [71] B.I. Drögemöller, R. Emsley, B. Chiliza, L. van der Merwe, G.E. Wright, M. Daya, E. Hoal, A.K. Malhotra, T. Lencz, D.G. Robinson, J.P. Zhang, L. Asmal, D.J. Niehaus, L. Warnich, The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first-episode schizophrenia patients, *Pharmacogenet Genomics* 26(5) (2016) 235-42.
- [72] Q. Li, N.E. Wineinger, D.J. Fu, O. Libiger, L. Alphas, A. Savitz, S. Gopal, N. Cohen, N.J. Schork, Genome-wide association study of paliperidone efficacy, *Pharmacogenet Genomics* 27(1) (2017) 7-18.
- [73] A. Alkelai, L. Greenbaum, E.L. Heinzen, E.H. Baugh, A. Teitelbaum, X. Zhu, R.D. Strous, P. Tatarsky, C.C. Zai, A.K. Tiwari, M. Tampakeras, N. Freeman, D.J. Müller, A.N. Voineskos, J.A. Lieberman, S.L. Delaney, H.Y. Meltzer, G. Remington, J.L. Kennedy, A.E. Pulver, E.P. Peabody, D.L. Levy, B. Lerer, New insights into tardive dyskinesia genetics: Implementation of whole-exome sequencing approach, *Prog Neuropsychopharmacol Biol Psychiatry* 94 (2019) 109659.
- [74] J.D. Allen, J.R. Bishop, A systematic review of genome-wide association studies of antipsychotic response, *Pharmacogenomics* 20(4) (2019) 291-306.
- [75] Q. Wang, H. Man Wu, W. Yue, H. Yan, Y. Zhang, L. Tan, W. Deng, Q. Chen, G. Yang, T. Lu, L. Wang, F. Zhang, J. Yang, K. Li, L. Lv, Q. Tan, H. Zhang, X. Ma, F. Yang, L. Li, C. Wang, L. Zhao, H. Ren, H. Yu, Y. Wang, X. Hu, D. Zhang, P. Sham, T. Li, C.A.P. Consortium, Effect of Damaging Rare Mutations in Synapse-Related Gene Sets on Response to Short-term Antipsychotic Medication in Chinese Patients With Schizophrenia: A Randomized Clinical Trial, *JAMA Psychiatry* 75(12) (2018) 1261-1269.
- [76] J. Sainz, C. Prieto, F. Ruso-Julve, B. Crespo-Facorro, Blood Gene Expression Profile Predicts Response to Antipsychotics, *Front Mol Neurosci* 11 (2018) 73.
- [77] F. Ruso-Julve, A. Pombero, F. Pilar-Cuéllar, N. García-Díaz, R. Garcia-Lopez, M. Juncal-Ruiz, E. Castro, Á. Díaz, J. Vazquez-Bourgón, A. García-Blanco, E. Garro-Martinez, H. Pisonero, A. Estirado, R. Ayesa-Arriola, J. López-Giménez, F. Mayor, E. Valdizán, J. Meana, J. Gonzalez-Maeso, S. Martínez, J.P. Vaqué, B. Crespo-Facorro, Dopaminergic control of ADAMTS2 expression through cAMP/CREB and ERK: molecular effects of antipsychotics, *Transl Psychiatry* 9(1) (2019) 306.
- [78] S. Garcia-Rosa, B.S. Carvalho, P.C. Guest, J. Steiner, D. Martins-de-Souza, Blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients, *J Proteomics* 224 (2020) 103813.
- [79] N. Fleeman, Y. Dundar, R. Dickson, A. Jorgensen, S. Pushpakom, C. McLeod, M. Pirmohamed, T. Walley, Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses, *Pharmacogenomics J* 11(1) (2011) 1-14.
- [80] M. Ingelman-Sundberg, Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future, *Trends Pharmacol Sci* 25(4) (2004) 193-200.
- [81] M.J. Arranz, A. Gonzalez-Rodriguez, J. Perez-Blanco, R. Penadés, B. Gutierrez, L. Ibañez, B. Arias, M. Brunet, J. Cervilla, J. Salazar, R. Catalan, A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments, *Transl Psychiatry* 9(1) (2019) 177.



- [82] L.M. Walden, E.J. Brandl, A.K. Tiwari, S. Cheema, N. Freeman, N. Braganza, J.L. Kennedy, D.J. Müller, Genetic testing for CYP2D6 and CYP2C19 suggests improved outcome for antidepressant and antipsychotic medication, *Psychiatry Res* 279 (2019) 111-115.
- [83] C.A. Bousman, B.W. Dunlop, Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools, *Pharmacogenomics J* 18(5) (2018) 613-622.
- [84] C.A. Altar, J.M. Carhart, J.D. Allen, D.K. Hall-Flavin, B.M. Dechairo, J.G. Winner, Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes, *Pharmacogenomics J* 15(5) (2015) 443-51.
- [85] D.K. Hall-Flavin, J.G. Winner, J.D. Allen, J.J. Jordan, R.S. Nesheim, K.A. Snyder, M.S. Drews, L.L. Eisterhold, J.M. Biernacka, D.A. Mrazek, Using a pharmacogenomic algorithm to guide the treatment of depression, *Transl Psychiatry* 2 (2012) e172.
- [86] C.A. Bousman, P. Jaksa, C. Pantelis, Systematic evaluation of commercial pharmacogenetic testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting, *Pharmacogenetics Genomics* (2017).
- [87] C.A. Bousman, K. Arandjelovic, S.G. Mancuso, H.A. Eyre, B.W. Dunlop, Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials, *Pharmacogenomics* 20(1) (2019) 37-47.
- [88] V. Pérez, A. Salavert, J. Espadaler, M. Tuson, J. Saiz-Ruiz, C. Sáez-Navarro, J. Bobes, E. Baca-García, E. Vieta, J.M. Olivares, R. Rodríguez-Jimenez, J.M. Villagrán, J. Gascón, J. Cañete-Crespillo, M. Solé, P.A. Saiz, Á. Ibáñez, J. de Diego-Adeliño, J.M. Menchón, A.-G.C. Group, Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial, *BMC Psychiatry* 17(1) (2017) 250.
- [89] J. Fagerness, E. Fonseca, G.P. Hess, R. Scott, K.R. Gardner, M. Koffler, M. Fava, R. Perlis, F.X. Brennan, J. Lombard, Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings, *Am J Manag Care* 20(5) (2014) e146-56.
- [90] J.K. Hicks, J.R. Bishop, K. Sangkuhl, D.J. Müller, Y. Ji, S.G. Leckband, J.S. Leeder, R.L. Graham, D.L. Chiulli, A. Llerena, T.C. Skaar, S.A. Scott, J.C. Stingl, T.E. Klein, K.E. Caudle, A. Gaedigk, C.P.I. Consortium, Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors, *Clin Pharmacol Ther* 98(2) (2015) 127-34.
- [91] J.K. Hicks, K. Sangkuhl, J.J. Swen, V.L. Ellingrod, D.J. Müller, K. Shimoda, J.R. Bishop, E.D. Kharasch, T.C. Skaar, A. Gaedigk, H.M. Dunnenberger, T.E. Klein, K.E. Caudle, J.C. Stingl, Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update, *Clin Pharmacol Ther* 102(1) (2017) 37-44.
- [92] J.J. Swen, M. Nijenhuis, A. de Boer, L. Grandia, A.H. Maitland-van der Zee, H. Mulder, G.A. Rongen, R.H. van Schaik, T. Schalekamp, D.J. Touw, J. van der Weide, B. Wilffert, V.H. Deneer, H.J. Guchelaar, Pharmacogenetics: from bench to byte--an update of guidelines, *Clin Pharmacol Ther* 89(5) (2011) 662-73.
- [93] J. de Leon, Personalizing dosing of risperidone, paliperidone and clozapine using therapeutic drug monitoring and pharmacogenetics, *Neuropharmacology* 168 (2020) 107656.
- [94] R. Grădinaru, N. Andreescu, L. Nussbaum, L. Suci, M. Puiu, Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients, *Ir J Med Sci* 188(4) (2019) 1417-1422.
- [95] S.G. Kang, I.S. Chee, K. Lee, J. Lee, rs7968606 polymorphism of ANKS1B is associated with improvement in the PANSS general score of schizophrenia caused by amisulpride, *Hum Psychopharmacol* 32(2) (2017).
- [96] D. Garfunkel, E.A. Anagnostou, M.G. Aman, B.L. Handen, K.B. Sanders, E.A. Macklin, J. Chan, J. Veenstra-VanderWeele, Pharmacogenetics of Metformin for Medication-Induced Weight Gain in Autism Spectrum Disorder, *J Child Adolesc Psychopharmacol* 29(6) (2019) 448-455.

- [97] J.R. Bishop, V.L. Ellingrod, J. Moline, D. Miller, Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment, *Schizophr Res* 77(2-3) (2005) 253-60.
- [98] A.K. Tiwari, E.J. Brandl, C.C. Zai, V.F. Goncalves, N.I. Chowdhury, N. Freeman, J.A. Lieberman, H.Y. Meltzer, J.L. Kennedy, D.J. Müller, Association of orexin receptor polymorphisms with antipsychotic-induced weight gain, *World J Biol Psychiatry* 17(3) (2016) 221-9.
- [99] C.C. Zai, F.H. Lee, A.K. Tiwari, J.Y. Lu, V. de Luca, M.S. Maes, D. Herbert, A. Shahmirian, S.Y. Cheema, G.C. Zai, A. Atukuri, M. Sherman, S.A. Shaikh, M. Tampakeras, N. Freeman, N. King, D.J. Müller, L. Greenbaum, B. Lerer, A.N. Voineskos, S.G. Potkin, J.A. Lieberman, H.Y. Meltzer, G. Remington, J.L. Kennedy, Investigation of the, *Front Pharmacol* 9 (2018) 974.
- [100] I. Spellmann, M. Riedel, J. Städtler, P. Zill, M. Obermeier, A. Cerovecki, S. Dehning, R. Schennach, M. Epple, M. Opgen-Rhein, N. Müller, B. Bondy, H.J. Möller, R. Musil, Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment, *Cogn Neuropsychiatry* 22(4) (2017) 280-297.
- [101] L. Yang, J. Chen, Y. Li, Y. Wang, S. Liang, Y. Shi, S. Shi, Y. Xu, Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics, *World J Biol Psychiatry* 17(6) (2016) 467-74.